Found 44 matching trials
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. PHASE2 This study assessed pasireotide LAR efficacy on patients with non-functioni...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Phase I Trial of Combination of FOLFIRI and SOM 230 PHASE1 This is a single-arm, open-label, phase I study of combination therapy with...
Show More Location
H. Lee Moffitt Cancer Center and Research Institute
Learn More & Join Trial
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer PHASE1 The goal of this clinical research study is to learn if the study drug SOM ...
Show More Location
H. Lee Moffitt Cancer Center and Research Institute
Learn More & Join Trial
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies PHASE4 The purpose of this study is to allow continued use of pasireotide in patie...
Show More Location
Ximed Research SC - SOM230B2412
Learn More & Join Trial
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism PHASE2 To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasi...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) PHASE2 The goal of this clinical research study is to learn if the study drug, Pas...
Show More Location
Stanford Cancer Institute
Learn More & Join Trial
Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts PHASE3 Liver cysts are fluid filled cavities located in the liver. They are presen...
Show More Location
Radboud University Nijmegen Medical Center; Department of Gastroenterology & Hepatology
Learn More & Join Trial
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus PHASE2 Observe the safety/tolerability and effectiveness in terms of response rate...
Show More Location
Penn State Milton S. Hershey Medical Center
Learn More & Join Trial
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors PHASE2 This is a phase II, open-label, 12-month pilot study in 10 patients with si...
Show More Location
Neuroendocrine Unit and Pituitary Center, Columbia University
Learn More & Join Trial
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly PHASE4 The study was designed to investigate the optimal management of hyperglycem...
Show More Location
Diabetes and Endocrine Associates La Mesa Location
Learn More & Join Trial